Clay Siegell is an individual who played a vital role in the field of medicine. In 1998 he launched Seattle Genetics. The firm is a development and drug research company that is built by giving out medical solutions in the field of oncology. The company’s aim is come up with drugs that will only target to destroy the cancer cells without having any effect to healthy body cells.
Clay Siegell’s idea to combat and provide solutions to cancer started he was only 19 years old. A tragic incident happened, Siegell watched his father helplessly die of cancer, this is the time when he realized that the field of oncology struggling with limited resources to combat cancer. Currently, Clay Siegell is the Chief Executive Officer, President, and Chairman of the Seattle Genetics Board.
He began his professional career in medicine after he obtained a Bachelor of Science Degree in Zoology from the best renowned university, The University of Maryland. He focused his line of education in Genetics then he advanced his knowledge where he earned a Ph.D. in Genetics from the University of Washington. In addition to his studies, Clay has 70 publications to his names and holds 15 patents. Siegell is also a member of Alder Biopharmaceuticals, Washington Roundtable and Ultragenyx Pharmaceuticals Board of Directors.
Moreover, Of recent, the cancer cases have tremendously increased necessitating the large of more research and came up with a solution to resolve the issue. The firm, Seattle Genetics works around the clock to provide more efficient drugs to its patient with limited side effects. Clay siegell believes teamwork of intellectual people can drive best and keen research to come up with better solutions.
Clay Siegell has led his team of intellectuals in Seattle Genetics in coming up with antibody-drug conjugates (ADCs), a pioneer in the field of oncology. Seattle Genetics have signed up multiple strategic licenses with different industries to earn its drug development technology (ADC) industries include; GlaxoSmithKline, AbbVie, Pfizer and GeneTech (Roche). The collaboration has generated more than $340 million to date.
Consequently, Seattle Genetics as a firm they have a secured over $1.2 billion from their private sources and public offerings. Through innovation, technology and strategic partnership are key aspects guiding the company. Clay siegell aim is to have an impact in fighting cancer.